evolucumab

This page shows the latest evolucumab news and features for those working in and with pharma, biotech and healthcare.

Amgen's Repatha unclogs blocked arteries, says study

Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins

SMC rejects Amgen's Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light. The Scottish Medicines Consortium (SMC) has turned down Amgen's cholesterol-lowering treatment Repatha (evolucumab), citing a lack of “robust” data.
NICE persuaded to back Praluent as well as Repatha

drug. The scheme includes an undisclosed discount to the NHS and allows NICE to back Praluent and Amgen's rival Repatha (evolucumab), which had already agreed a price cut, in new

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Add my company

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...